Skip to main content
. 2024 Feb 28;271(5):2810–2823. doi: 10.1007/s00415-024-12236-0

Fig. 2.

Fig. 2

Change from baseline in a 6MWD (% predicted) and b sitting FVC (% predicted) in ERT-experienced patients (OLE-ES population). 6MWD 6-min walk distance; alg + pbo alglucosidase alfa + placebo; cipa + mig cipaglucosidase alfa + miglustat; ERT enzyme replacement therapy; FVC forced vital capacity; OLE-ES open-label extension enrolled subjects; SD standard deviation; SE standard error